Evolent Health (EVH) to Release Earnings on Thursday

Evolent Health (NYSE:EVH) will likely be posting its Q1 2026 results after the market closes on Thursday, May 7th. Analysts expect Evolent Health to post earnings of ($0.05) per share and revenue of $534.0020 million for the quarter. Individuals may visit the the company’s upcoming Q1 2026 earning results page for the latest details on the call scheduled for Thursday, May 7, 2026 at 8:00 AM ET.

Evolent Health (NYSE:EVH) last posted its earnings results on Tuesday, February 24th. The technology company reported $0.08 EPS for the quarter, beating analysts’ consensus estimates of $0.06 by $0.02. Evolent Health had a negative net margin of 28.49% and a positive return on equity of 1.49%. The company had revenue of $468.72 million for the quarter, compared to analysts’ expectations of $468.48 million. During the same quarter in the prior year, the company posted ($0.02) earnings per share. Evolent Health’s revenue for the quarter was down 27.5% compared to the same quarter last year. On average, analysts expect Evolent Health to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Evolent Health Trading Down 2.2%

NYSE EVH opened at $3.90 on Wednesday. The firm’s 50-day moving average is $2.88 and its two-hundred day moving average is $3.85. Evolent Health has a 12 month low of $2.10 and a 12 month high of $12.06. The company has a debt-to-equity ratio of 2.34, a current ratio of 1.31 and a quick ratio of 1.31. The stock has a market capitalization of $435.51 million, a P/E ratio of -0.76 and a beta of 0.83.

Institutional Trading of Evolent Health

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Virtu Financial LLC purchased a new stake in Evolent Health during the fourth quarter worth about $106,000. Invesco Ltd. increased its stake in Evolent Health by 30.4% during the fourth quarter. Invesco Ltd. now owns 392,282 shares of the technology company’s stock worth $1,569,000 after purchasing an additional 91,370 shares during the period. nVerses Capital LLC purchased a new stake in Evolent Health during the fourth quarter worth about $109,000. Tudor Investment Corp ET AL increased its stake in Evolent Health by 1.9% during the fourth quarter. Tudor Investment Corp ET AL now owns 702,121 shares of the technology company’s stock worth $2,808,000 after purchasing an additional 12,859 shares during the period. Finally, Quadrature Capital Ltd increased its stake in Evolent Health by 128.1% during the fourth quarter. Quadrature Capital Ltd now owns 159,815 shares of the technology company’s stock worth $639,000 after purchasing an additional 89,742 shares during the period.

Wall Street Analyst Weigh In

A number of research analysts have commented on the stock. Oppenheimer decreased their target price on shares of Evolent Health from $12.00 to $6.00 and set an “outperform” rating on the stock in a research report on Monday, March 2nd. Citigroup decreased their target price on shares of Evolent Health from $6.00 to $4.00 and set a “buy” rating on the stock in a research report on Thursday, February 26th. UBS Group decreased their target price on shares of Evolent Health from $10.00 to $5.00 and set a “buy” rating on the stock in a research report on Thursday, February 26th. TD Cowen reiterated a “buy” rating on shares of Evolent Health in a research note on Monday, March 2nd. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Evolent Health in a research note on Friday, March 27th. Thirteen research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $6.04.

About Evolent Health

Evolent Health, Inc is a U.S.-based healthcare technology and services company that partners with health systems, physician organizations and health plans to design, build and operate value-based care programs. Headquartered in Arlington, Virginia, the company was founded in 2011 as a joint venture between TPG and the University of Pittsburgh Medical Center (UPMC). Evolent Health aims to help its clients transition from fee-for-service payment models to value-based care arrangements by leveraging its proprietary technology platforms and clinical expertise.

The company’s core offerings include care management solutions, population health analytics and clinical advisory services.